Cargando…

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

OBJECTIVE: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakanishi, Shotaro, Goya, Masato, Tamaki, Mitsuyoshi, Oshiro, Takuma, Saito, Seiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176613/ https://www.ncbi.nlm.nih.gov/pubmed/34082809 http://dx.doi.org/10.1186/s13104-021-05641-5

Ejemplares similares

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
por: Tsuzuki, Shunsuke, et al.
Publicado: (2021)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient
por: Nakanishi, Shotaro, et al.
Publicado: (2019)

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
por: Ghosn, Marwan, et al.
Publicado: (2015)

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2022)

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer
por: Roy, Soumyajit, et al.
Publicado: (2023)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

Proceedings: Hormones and the prostate.
por: Griffiths, K.
Publicado: (1974)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
por: Pinkawa, Michael, et al.
Publicado: (2012)

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
por: Liu, Chang, et al.
Publicado: (2020)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
por: Narita, Takuma, et al.
Publicado: (2021)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion
por: Conrad, Fraser, et al.
Publicado: (2009)

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
por: Morant, R, et al.
Publicado: (2004)

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2rsmc06jsrobtgthcvpmttses8